ALLKのチャート
ALLKの企業情報
| symbol | ALLK |
|---|---|
| 会社名 | Allakos Inc （アラコス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Allakos Inc. is a clinical-stage biotechnology company which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells which are involved in allergy inflammation and tissue damage. Its lead program is AK002 which is an antibody that targets Siglec-8 an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells including eosinophilic gastritis (EG) indolent systemic mastocytosis urticaria and allergic conjunctivitis. アラコスは米国のバイオ医薬品企業。臨床段階で、アレルギ―性疾患、炎症性疾患および増殖性疾患の治療用抗体の開発に従事する。同社は、好酸球性胃炎および胃腸炎、じんま疹、無症候性全身性肥満細胞症、重度のアレルギ―性結膜炎の治療薬AK002を開発する。本社所在地はカリフォルニア州サン・カルロス。 Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. |
| 本社所在地 | 75 Shoreway Road Suite A San Carlos CA 94070 USA |
| 代表者氏名 | Christopher Bebbington Christopher Bebbington |
| 代表者役職名 | President Founder Director |
| 電話番号 | +1 650-597-5002 |
| 設立年月日 | 40969 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.allakos.com |
| nasdaq_url | https://www.nasdaq.com/symbol/allk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -30.66500 |
| 終値（lastsale） | 32.035 |
| 時価総額（marketcap） | 1349091845.065 |
| 時価総額 | 時価総額（百万ドル） 1485.749 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1564.622 |
| 当期純利益 | 当期純利益（百万ドル） -31.66600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Allakos Inc revenues was not reported. Net loss increased 83% to $17.9M. Higher net loss reflects Research and Development - Balancing increase of 64% to $13.2M (expense) General and Administrative - Balancing increase from $1.4M to $4M (expense) Stock-based Compensation in SGA increase from $86K to $718K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.24 to -$0.43. |
ALLKのテクニカル分析
ALLKのニュース
Allakos Inc. (ALLK) is an excellent investment, but the stock is overvalued/undervalued right now 2023/01/04 14:16:00 US Post News
A share of Allakos Inc. (NASDAQ:ALLK) closed at $8.27 per share on Tuesday, down from $8.42 day before. While Allakos Inc. has underperformed by -1.78%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLK fell by -15.53%, with highs and lows ranging from $10.19 to $2.54, […]
What To Expect As Allakos Inc. (NASDAQ: ALLK) Delivers An 178.81% Gain In 6 Months 2022/12/31 14:00:00 Marketing Sentinel
During the last session, Allakos Inc. (NASDAQ:ALLK)’s traded shares were 0.68 million, with the beta value of the company hitting 0.51. At the end of the trading day, the stock’s price was $8.42, reflecting an intraday gain of 2.43% or $0.2. The 52-week high for the ALLK share is $10.66, that puts it down -26.6 … What To Expect As Allakos Inc. (NASDAQ: ALLK) Delivers An 178.81% Gain In 6 Months Read More »
A stock that deserves closer examination: Allakos Inc. (ALLK) 2022/12/29 12:00:00 US Post News
In Wednesday’s session, Allakos Inc. (NASDAQ:ALLK) marked $7.40 per share, down from $7.47 in the previous session. While Allakos Inc. has underperformed by -0.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLK fell by -26.66%, with highs and lows ranging from $10.66 to $2.54, whereas […]
How should investors view Allakos Inc. (ALLK)? 2022/12/21 16:48:00 US Post News
In Tuesday’s session, Allakos Inc. (NASDAQ:ALLK) marked $6.97 per share, up from $6.95 in the previous session. While Allakos Inc. has overperformed by 0.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLK fell by -91.44%, with highs and lows ranging from $84.94 to $2.54, whereas […]
The Allakos Inc. (ALLK) had a good session last reading, didn’t it? 2022/12/15 12:32:00 US Post News
In Wednesday’s session, Allakos Inc. (NASDAQ:ALLK) marked $7.01 per share, down from $7.08 in the previous session. While Allakos Inc. has underperformed by -0.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLK fell by -91.40%, with highs and lows ranging from $86.95 to $2.54, whereas […]
What To Expect As Allakos Inc. (NASDAQ: ALLK) Delivers An 178.81% Gain In 6 Months 2022/12/31 14:00:00 Marketing Sentinel
During the last session, Allakos Inc. (NASDAQ:ALLK)’s traded shares were 0.68 million, with the beta value of the company hitting 0.51. At the end of the trading day, the stock’s price was $8.42, reflecting an intraday gain of 2.43% or $0.2. The 52-week high for the ALLK share is $10.66, that puts it down -26.6 … What To Expect As Allakos Inc. (NASDAQ: ALLK) Delivers An 178.81% Gain In 6 Months Read More »
A stock that deserves closer examination: Allakos Inc. (ALLK) 2022/12/29 12:00:00 US Post News
In Wednesday’s session, Allakos Inc. (NASDAQ:ALLK) marked $7.40 per share, down from $7.47 in the previous session. While Allakos Inc. has underperformed by -0.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLK fell by -26.66%, with highs and lows ranging from $10.66 to $2.54, whereas […]
How should investors view Allakos Inc. (ALLK)? 2022/12/21 16:48:00 US Post News
In Tuesday’s session, Allakos Inc. (NASDAQ:ALLK) marked $6.97 per share, up from $6.95 in the previous session. While Allakos Inc. has overperformed by 0.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLK fell by -91.44%, with highs and lows ranging from $84.94 to $2.54, whereas […]
The Allakos Inc. (ALLK) had a good session last reading, didn’t it? 2022/12/15 12:32:00 US Post News
In Wednesday’s session, Allakos Inc. (NASDAQ:ALLK) marked $7.01 per share, down from $7.08 in the previous session. While Allakos Inc. has underperformed by -0.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALLK fell by -91.40%, with highs and lows ranging from $86.95 to $2.54, whereas […]
Allakos Inc. (NASDAQ: ALLK): Can A Stock Be -27.99% Lower Year-To-Date And Still Be A Loser? 2022/11/11 13:30:00 Marketing Sentinel
Allakos Inc. (NASDAQ:ALLK)’s traded shares stood at 1.17 million during the last session, with the company’s beta value hitting 0.40. At the close of trading, the stock’s price was $7.05, to imply an increase of 5.86% or $0.39 in intraday trading. The ALLK share’s 52-week high remains $88.67, putting it -1157.73% down since that peak … Allakos Inc. (NASDAQ: ALLK): Can A Stock Be -27.99% Lower Year-To-Date And Still Be A Loser? Read More »
Allakos Inc. (NASDAQ: ALLK): Can A Stock Be -27.99% Lower Year-To-Date And Still Be A Loser? 2022/11/11 13:30:00 Marketing Sentinel
Allakos Inc. (NASDAQ:ALLK)’s traded shares stood at 1.17 million during the last session, with the company’s beta value hitting 0.40. At the close of trading, the stock’s price was $7.05, to imply an increase of 5.86% or $0.39 in intraday trading. The ALLK share’s 52-week high remains $88.67, putting it -1157.73% down since that peak … Allakos Inc. (NASDAQ: ALLK): Can A Stock Be -27.99% Lower Year-To-Date And Still Be A Loser? Read More »
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday 2022/11/09 10:08:43 Benzinga
Gainers Unique Fabricating, Inc. (NYSE: UFAB ) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. TaskUs, Inc. (NASDAQ: TASK ) shares jumped 37.2% to settle at $22.01 on Tuesday after the company reported better-than-expected Q3 results. The company also issued Q4 and FY22 sales guidance above analyst estimates. GrowGeneration Corp. (NASDAQ: GRWG ) shares jumped 35.1% to close at $4.47 after the company reported better-than-expected Q3 sales. SkyWater Technology, Inc. (NASDAQ: SKYT ) gained 31.6% to close at $11.37 after the company reported better-than-expected Q3 EPS and sales results. Groupon, Inc. (NASDAQ: GRPN ) gained 27.4% to settle at $8.97 following Q3 results. Oportun Financial Corporation (NASDAQ: OPRT ) climbed 26.8% to close at $5.26 after the company announced upbeat Q3 results. National CineMedia, Inc. (NASDAQ: NCMI ) gained 26.2% to settle at $0.5451 after the company reported Q3 results.
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday''s Mid-Day Session 2022/11/08 17:51:49 Benzinga
Gainers IceCure Medical Ltd (NASDAQ: ICCM ) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast cancer cryoablation procedures. TaskUs, Inc. (NASDAQ: TASK ) shares climbed 37.1% to $21.99 after the company reported better-than-expected Q3 results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Oportun Financial Corporation (NASDAQ: OPRT ) gained 36.1% to $5.65 after the company announced upbeat Q3 results. GrowGeneration Corp. (NASDAQ: GRWG ) shares climbed 29.9% to $4.30 after the company reported better-than-expected Q3 sales. SkyWater Technology, Inc. (NASDAQ: SKYT ) gained 25.8% to $10.87 after the company reported better-than-expected Q3 EPS and sales results. Exela Technologies, Inc. (NASDAQ: XELA ) rose 25% to $0.2161. Allakos Inc. (NASDAQ: ALLK ) jumped 25% to $7.65 following a narrower-than-expected Q3 loss. Triumph Group, Inc. (NYSE: TGI ) surged 23.7% to $11.77 after the company reported upbeat quarterly sales and raised FY23 earnings guidance.